Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Vedolizumab recommended for ulcerative colitis

The National Institute for Health and Care Excellence (NICE) has issued final guidance that recommends vedolizumab (Entyvio; Takeda) as an option to treat moderate to severely active ulcerative colitis. Vedolizumab is recommended on the basis that it will be provided to the NHS at a reduced price.

  • This noticeboard item was updated on 12 June 2015 to correct the name of vedolizumab

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068712

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.